Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-10-Speech-1-243-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-09-10"^^xsd:date2
dcterms:Is Part Of	lp_eu:Pharmacovigilance (amendment of Directive 2001/83/EC) - Pharmacovigilance (amendment of Regulation (EC) No 726/2004) (debate)2
dcterms:Language	"pl"^^xsd:language2
lpv:document identification number	"en.20120910.29.1-243-000"2
lpv:hasSubsequent	lp_eu:2012-09-10-Speech-1-244-0002
lpv:speaker	lp:Róża Gräfin von Thun Und Hohenstein2
lpv:spokenAs	unknown; Platforma Obywatelska (2009-07-14--2014-06-30)3 substitute; CULT (2012-01-19--2014-06-30)3 member; IMCO (2012-01-19--2014-06-30)3 member; Delegation to the Parliamentary Assembly of the Union for the Mediterranean (2009-09-16--2014-06-30)3 substitute; Delegation for relations with the Palestinian Legislative Council (2009-09-16--2014-06-30)3 member; EPP (2009-07-14--2014-06-30)3 member; Delegation for relations with Israel (2009-09-16--2014-06-30)3
lpv:translated text	"Madam President, it is really positive that the Commission has proposed to review the Pharmacovigilance Directive. The safety of pharmaceuticals available in the single market is, indeed, of paramount importance to citizens. The European Parliament, as well as other European institutions, must continue their systematic efforts, doing their utmost, in these changing times and retail conditions, to ensure that citizens can be certain about products that are available not only in shops and pharmacies but also online. The case of the medicine named Mediator, which we are discussing here, triggered the revision of this directive and the pharmacovigilance regulation. This is certainly a step in the right direction. We must improve supervision of products being sold in the single market. There are many counterfeit products and many extremely dangerous substances, and there are no warnings or campaigns which inform citizens and consumers which sources are dangerous, how a medicine can be verified, and where not to buy them. Any counterfeit products may be very dangerous, but here we really are talking about a direct threat to human health and life. The citizens are not being adequately informed about the consequences of taking a particular substance. I fully agree with Peter Liese, who states that information is often overly complicated and sometimes incomplete. This is why I extend my special congratulations to Peter Liese and Anja Weisgerber in connection with the drug facts box initiative. Indeed, it is likely to benefit the consumers of medications and may lead to a regime which would require clarity of information regarding the content and effects of particular substances. And a brief question to Commissioner Dalli. You referred to consultations. I have been present at some of these consultations, and I ask once again: in how many languages are they conducted? Are they accessible by people and institutions that do not use English?"@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph